Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CNTB Stock Forecast 2026-2027
$2.20
Current Price
$138.84M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CNTB Price Targets
+354.5%
To High Target of $10.00
+218.2%
To Median Target of $7.00
+81.8%
To Low Target of $4.00
CNTB Price Momentum
+2.3%
1 Week Change
-6.8%
1 Month Change
+182.1%
1 Year Change
-22.0%
Year-to-Date Change
-42.4%
From 52W High of $3.82
+192.2%
From 52W Low of $0.75
📊 TOP ANALYST CALLS
Did CNTB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Connect Biopharma is one of their latest high-conviction picks.
Latest CNTB Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, CNTB has a bullish consensus with a median price target of $7.00 (ranging from $4.00 to $10.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $2.20, the median forecast implies a 218.2% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Olivia Brayer at Cantor Fitzgerald, suggesting a 81.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CNTB Analyst Ratings
7
Buy
0
Hold
0
Sell
CNTB Price Target Range
Low
$4.00
Average
$7.00
High
$10.00
Current: $2.20
Latest CNTB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CNTB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 26, 2026 | Canaccord Genuity | Edward Nash | Buy | Initiates | $6.00 |
| May 21, 2026 | Cantor Fitzgerald | Olivia Brayer | Overweight | Initiates | $4.00 |
| Apr 1, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Mar 31, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Dec 1, 2025 | Lake Street | Buy | Initiates | $N/A | |
| Nov 13, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Oct 31, 2025 | BTIG | Buy | Initiates | $N/A | |
| Aug 13, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 12, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $7.00 |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 31, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 6, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 13, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 17, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 4, 2024 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Sep 13, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Feb 8, 2023 | SVB Leerink | Outperform | Maintains | $N/A | |
| Jun 2, 2022 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| May 5, 2022 | Piper Sandler | Neutral | Downgrade | $N/A | |
| May 4, 2022 | SVB Leerink | Outperform | Maintains | $N/A |
Connect Biopharma Holdings Ltd. (CNTB) Competitors
The following stocks are similar to Connect Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CNTB
Connect Biopharma
mkt cap
136.63M
Connect Biopharma Holdings Ltd. (CNTB) Financial Data
Connect Biopharma Holdings Ltd. has a market capitalization of $138.84M with a P/E ratio of -2.2x. The company generates $233,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -11,601.8% and return on equity of -102.9%.
Valuation Metrics
Market Cap
$138.84M
Enterprise Value
$91.29M
P/E Ratio
-2.2x
PEG Ratio
0.0x
Price/Sales
586.4x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-11,601.8%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+33.2%
Current Ratio
3.2x
Debt/Equity
1.6x
ROE
-102.9%
ROA
-54.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Connect Biopharma Holdings Ltd. (CNTB) Business Model
About Connect Biopharma Holdings Ltd.
What They Do
Develops therapies for inflammatory diseases.
Business Model
Connect Biopharma Holdings Ltd. operates as a clinical-stage biopharmaceutical company that focuses on creating innovative therapies for T cell-driven inflammatory diseases. The company generates revenue through the development and potential commercialization of its proprietary drugs, including rademikibart and icanbelimod, both targeting specific chronic inflammatory conditions.
Additional Information
Headquartered in San Diego, California, with operations in the United States and China, Connect Biopharma is advancing its product candidates through various clinical trial phases, with a focus on improving treatment outcomes for patients suffering from conditions like atopic dermatitis, asthma, ulcerative colitis, and Crohn's disease.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
64
CEO
Dr. Barry D. Quart Pharm.D.
Country
United States
IPO Year
2020
Website
www.connectbiopharm.comConnect Biopharma Holdings Ltd. (CNTB) Latest News & Analysis
Latest News
Quick Summary
Connect Biopharma (NASDAQ: CNTB) CEO Barry Quart reported positive indicators for the rademikibart program, pending mid-2026 data from the SEABREEZE study.
Why It Matters
The positive update on rademikibart's clinical profile and upcoming 2026 data could influence investor sentiment and stock performance for Connect Biopharma.
Source: MarketBeat
Market Sentiment:
Positive
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
27 days ago
Quick Summary
Phase 2 Seabreeze STAT studies for asthma and COPD are proceeding as scheduled following an independent review of the interim analysis by the Data Monitoring Committee.
Why It Matters
Continued progress in Phase 2 studies for asthma and COPD suggests potential for successful drug development, which can impact stock performance and market valuation for the involved company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
27 days ago
Quick Summary
Connect Biopharma Holdings Limited (Nasdaq: CNTB) will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 19, 2026, at 9:30 a.m. ET.
Why It Matters
Connect Biopharma's participation in a major investor conference highlights its visibility and potential for investment interest, signaling developments in its clinical-stage pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Connect Biopharma Holdings is rated a risky Buy, with potential upside based on mid-2026 Phase 2 trial results for rademikibart, showing promise against Dupixent in asthma and COPD markets.
Why It Matters
Connect Biopharma Holdings presents a high-risk, high-reward opportunity due to promising trial results for rademikibart, targeting a lucrative market with no current competition.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Connect Biopharma's Phase 2 Seabreeze STAT trials for rademikibart in asthma and COPD will proceed without changes to sample size, as confirmed by the Data Monitoring Committee's interim analysis.
Why It Matters
The DMC's decision to maintain the sample size suggests confidence in the drug's efficacy, which could enhance Connect Biopharma's stock value and attract investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
2 months ago
Quick Summary
Connect Biopharma reported positive Phase 1 data for IV rademikibart in asthma/COPD and ongoing Phase 2 studies. They secured $20.2M in equity financing, extending cash runway into H2 2027.
Why It Matters
Positive Phase 1 data for rademikibart boosts confidence in its potential for asthma and COPD, while $20.2M financing extends the company's operational runway, signaling growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CNTB Stock
What is Connect Biopharma Holdings Ltd.'s (CNTB) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Connect Biopharma Holdings Ltd. (CNTB) has a median price target of $7.00. The highest price target is $10.00 and the lowest is $4.00.
Is CNTB stock a good investment in 2026?
According to current analyst ratings, CNTB has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CNTB stock?
Wall Street analysts predict CNTB stock could reach $7.00 in the next 12 months. This represents a 218.2% increase from the current price of $2.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Connect Biopharma Holdings Ltd.'s business model?
Connect Biopharma Holdings Ltd. operates as a clinical-stage biopharmaceutical company that focuses on creating innovative therapies for T cell-driven inflammatory diseases. The company generates revenue through the development and potential commercialization of its proprietary drugs, including rademikibart and icanbelimod, both targeting specific chronic inflammatory conditions.
What is the highest forecasted price for CNTB Connect Biopharma Holdings Ltd.?
The highest price target for CNTB is $10.00 from at , which represents a 354.5% increase from the current price of $2.20.
What is the lowest forecasted price for CNTB Connect Biopharma Holdings Ltd.?
The lowest price target for CNTB is $4.00 from Olivia Brayer at Cantor Fitzgerald, which represents a 81.8% increase from the current price of $2.20.
What is the overall CNTB consensus from analysts for Connect Biopharma Holdings Ltd.?
The overall analyst consensus for CNTB is bullish. Out of 4 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are CNTB stock price projections?
Stock price projections, including those for Connect Biopharma Holdings Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 2:30 AM UTC